Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study. (2023). SKIN The Journal of Cutaneous Medicine, 7(6), s258. https://doi.org/10.25251/skin.7.supp.258